191 related articles for article (PubMed ID: 20605877)
1. B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus.
Goeken JA; Layer T; Fleenor S; Laccheo M; Lenert P
Lupus; 2010 Oct; 19(11):1290-301. PubMed ID: 20605877
[TBL] [Abstract][Full Text] [Related]
2. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
Brummel R; Roberts TL; Stacey KJ; Lenert P
Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
[TBL] [Abstract][Full Text] [Related]
3. Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus.
Lindau D; Rönnefarth V; Erbacher A; Rammensee HG; Decker P
Eur J Immunol; 2011 Mar; 41(3):669-81. PubMed ID: 21287547
[TBL] [Abstract][Full Text] [Related]
4. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
[TBL] [Abstract][Full Text] [Related]
5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
6. TLR9 in peritoneal B-1b cells is essential for production of protective self-reactive IgM to control Th17 cells and severe autoimmunity.
Stoehr AD; Schoen CT; Mertes MM; Eiglmeier S; Holecska V; Lorenz AK; Schommartz T; Schoen AL; Hess C; Winkler A; Wardemann H; Ehlers M
J Immunol; 2011 Sep; 187(6):2953-65. PubMed ID: 21859955
[TBL] [Abstract][Full Text] [Related]
7. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
[TBL] [Abstract][Full Text] [Related]
8. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
[TBL] [Abstract][Full Text] [Related]
9. Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro.
Im Hof M; Williamson L; Summerfield A; Balmer V; Dutoit V; Kandimalla ER; Yu D; Zurbriggen A; Doherr MG; Peel J; Roosje PJ
Vet Immunol Immunopathol; 2008 Jul; 124(1-2):120-31. PubMed ID: 18452997
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE.
Yu P; Wellmann U; Kunder S; Quintanilla-Martinez L; Jennen L; Dear N; Amann K; Bauer S; Winkler TH; Wagner H
Int Immunol; 2006 Aug; 18(8):1211-9. PubMed ID: 16798839
[TBL] [Abstract][Full Text] [Related]
11. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
12. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC.
Meyers JA; Mangini AJ; Nagai T; Roff CF; Sehy D; van Seventer GA; van Seventer JM
Cytokine; 2006 Sep; 35(5-6):235-46. PubMed ID: 17052915
[TBL] [Abstract][Full Text] [Related]
13. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE.
Ehlers M; Fukuyama H; McGaha TL; Aderem A; Ravetch JV
J Exp Med; 2006 Mar; 203(3):553-61. PubMed ID: 16492804
[TBL] [Abstract][Full Text] [Related]
14. Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses.
Nündel K; Green NM; Shaffer AL; Moody KL; Busto P; Eilat D; Miyake K; Oropallo MA; Cancro MP; Marshak-Rothstein A
J Immunol; 2015 Mar; 194(6):2504-12. PubMed ID: 25681333
[TBL] [Abstract][Full Text] [Related]
15. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation.
Dil N; Marshall AJ
Mol Immunol; 2009 Jun; 46(10):1970-8. PubMed ID: 19362372
[TBL] [Abstract][Full Text] [Related]
16. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
17. 17β-Estradiol enhances response of mice spleen B cells elicited by TLR9 agonist.
Xu Y; Fan H; Li X; Sun L; Hou Y
Cell Immunol; 2012; 278(1-2):125-35. PubMed ID: 22960279
[TBL] [Abstract][Full Text] [Related]
18. TLR9 signaling failure renders Peyer's patch regulatory B cells unresponsive to stimulation with CpG oligodeoxynucleotides.
Booth JS; Arsenault R; Napper S; Griebel PJ; Potter AA; Babiuk LA; Mutwiri GK
J Innate Immun; 2010; 2(5):483-94. PubMed ID: 20551621
[TBL] [Abstract][Full Text] [Related]
19. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function.
Jiang W; Lederman MM; Harding CV; Rodriguez B; Mohner RJ; Sieg SF
Eur J Immunol; 2007 Aug; 37(8):2205-13. PubMed ID: 17621369
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.
Christensen SR; Shupe J; Nickerson K; Kashgarian M; Flavell RA; Shlomchik MJ
Immunity; 2006 Sep; 25(3):417-28. PubMed ID: 16973389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
